D K Armstrong
Overview
Explore the profile of D K Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
877
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasner C, Castro C, Penson R, Roche M, Matulonis U, Morgan M, et al.
Gynecol Oncol
. 2019 Feb;
153(2):223-229.
PMID: 30765148
Background: Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen...
2.
Provencher D, Gallagher C, Parulekar W, Ledermann J, Armstrong D, Brundage M, et al.
Ann Oncol
. 2017 Nov;
29(2):431-438.
PMID: 29186319
Background: The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in...
3.
Simon R, Blumenthal G, Rothenberg M, Sommer J, Roberts S, Armstrong D, et al.
Clin Pharmacol Ther
. 2015 Feb;
97(5):502-7.
PMID: 25676488
Although randomized trials provide the most reliable evidence of a drug's safety and efficacy, there are situations where randomized trials are not possible or ethical. In this article we discuss...
4.
Lesnock J, Darcy K, Tian C, Deloia J, Thrall M, Zahn C, et al.
Br J Cancer
. 2013 Mar;
108(6):1231-7.
PMID: 23462720
Background: Breast cancer 1, early onset (BRCA1) is a tumour-suppressor gene associated with familial epithelial ovarian cancer (EOC). Reduced BRCA1 expression is associated with enhanced sensitivity to platinum-based chemotherapy. We...
5.
Giuntoli 2nd R, Bristow R, Diaz-Montes T, Armstrong D
J Chemother
. 2011 Jul;
23(3):163-7.
PMID: 21742586
The goal of this study is to determine the feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of patients with ovarian cancer. We performed a retrospective...
6.
Visvanathan K, Santor D, Ali S, Brewster A, Arnold A, Armstrong D, et al.
Cancer Epidemiol Biomarkers Prev
. 2007 May;
16(5):950-5.
PMID: 17507621
Purpose: Ductal lavage, a technique used to sample epithelial cells from breast ducts, has potential use in risk assessment and biomarker evaluation among women at increased risk for breast cancer....
7.
Seiden M, Burris H, Matulonis U, Hall J, Armstrong D, Speyer J, et al.
Gynecol Oncol
. 2006 Nov;
104(3):727-31.
PMID: 17126894
Objective: The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer. Secondary end points included...
8.
Thrall M, Gallion H, Kryscio R, Kapali M, Armstrong D, DeLoia J
Int J Gynecol Cancer
. 2006 Mar;
16 Suppl 1:166-71.
PMID: 16515585
BRCA1 is a tumor suppressor gene that, when mutated, is associated with the development of hereditary ovarian cancer. A role for BRCA1 in the pathoetiology of sporadic ovarian epithelial cancer...
9.
Armstrong D, Davidson N
Breast Dis
. 2005 Feb;
14:91-7.
PMID: 15687639
Strategies utilizing high-dose chemotherapy for treatment of breast cancer have been the subject of significant controversy over the past decade. Disappointing results from randomized phase III trials in metastatic and...
10.
Rudek M, Sparreboom A, Garrett-Mayer E, Armstrong D, Wolff A, Verweij J, et al.
Eur J Cancer
. 2004 Apr;
40(8):1170-8.
PMID: 15110880
Current dosing strategies for anticancer drugs result in wide interindividual pharmacokinetic variability. Here, we explored the influence of age, body size, concomitant drugs, dose, infusion duration, and sex on the...